nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—adrenal gland cancer	0.501	1	CtDrD
Crizotinib—IGF1R—adrenal gland cancer	0.299	0.89	CbGaD
Crizotinib—ABCB1—adrenal gland cancer	0.037	0.11	CbGaD
Crizotinib—STK10—renal vein—adrenal gland cancer	0.00493	0.076	CbGeAlD
Crizotinib—STK10—renal artery—adrenal gland cancer	0.00331	0.0511	CbGeAlD
Crizotinib—SRC—adrenal medulla—adrenal gland cancer	0.00247	0.0382	CbGeAlD
Crizotinib—IKBKE—adrenal gland—adrenal gland cancer	0.000703	0.0108	CbGeAlD
Crizotinib—ANKK1—adrenal gland—adrenal gland cancer	0.000703	0.0108	CbGeAlD
Crizotinib—PRKD3—adrenal cortex—adrenal gland cancer	0.000612	0.00944	CbGeAlD
Crizotinib—NEK9—gonad—adrenal gland cancer	0.000578	0.00892	CbGeAlD
Crizotinib—MAPK7—adrenal cortex—adrenal gland cancer	0.000565	0.00872	CbGeAlD
Crizotinib—PRKD1—gonad—adrenal gland cancer	0.000527	0.00813	CbGeAlD
Crizotinib—PRKD3—gonad—adrenal gland cancer	0.000507	0.00782	CbGeAlD
Crizotinib—PRKD3—pituitary gland—adrenal gland cancer	0.000494	0.00763	CbGeAlD
Crizotinib—DSTYK—pituitary gland—adrenal gland cancer	0.000482	0.00744	CbGeAlD
Crizotinib—MAPK7—gonad—adrenal gland cancer	0.000468	0.00722	CbGeAlD
Crizotinib—PRKD1—adrenal gland—adrenal gland cancer	0.000459	0.00709	CbGeAlD
Crizotinib—MAPK7—pituitary gland—adrenal gland cancer	0.000457	0.00705	CbGeAlD
Crizotinib—LIMK1—adrenal gland—adrenal gland cancer	0.000453	0.00699	CbGeAlD
Crizotinib—PRKD3—adrenal gland—adrenal gland cancer	0.000442	0.00681	CbGeAlD
Crizotinib—DSTYK—adrenal gland—adrenal gland cancer	0.000431	0.00665	CbGeAlD
Crizotinib—MET—pituitary gland—adrenal gland cancer	0.000427	0.0066	CbGeAlD
Crizotinib—BLK—adrenal gland—adrenal gland cancer	0.000426	0.00657	CbGeAlD
Crizotinib—CASK—adrenal gland—adrenal gland cancer	0.000421	0.0065	CbGeAlD
Crizotinib—TAOK2—pituitary gland—adrenal gland cancer	0.00041	0.00633	CbGeAlD
Crizotinib—MAPK7—adrenal gland—adrenal gland cancer	0.000408	0.00629	CbGeAlD
Crizotinib—TXK—adrenal gland—adrenal gland cancer	0.000408	0.00629	CbGeAlD
Crizotinib—ACVR1B—gonad—adrenal gland cancer	0.000405	0.00625	CbGeAlD
Crizotinib—TIE1—adrenal cortex—adrenal gland cancer	0.000404	0.00624	CbGeAlD
Crizotinib—STK3—adrenal cortex—adrenal gland cancer	0.000404	0.00624	CbGeAlD
Crizotinib—FES—adrenal gland—adrenal gland cancer	0.000404	0.00623	CbGeAlD
Crizotinib—TESK1—adrenal cortex—adrenal gland cancer	0.000391	0.00603	CbGeAlD
Crizotinib—EPHA6—gonad—adrenal gland cancer	0.000386	0.00596	CbGeAlD
Crizotinib—MET—adrenal gland—adrenal gland cancer	0.000382	0.00589	CbGeAlD
Crizotinib—PLK4—gonad—adrenal gland cancer	0.000382	0.00589	CbGeAlD
Crizotinib—MERTK—adrenal cortex—adrenal gland cancer	0.00038	0.00587	CbGeAlD
Crizotinib—DCLK1—pituitary gland—adrenal gland cancer	0.000375	0.00578	CbGeAlD
Crizotinib—CDK7—adrenal gland—adrenal gland cancer	0.000369	0.0057	CbGeAlD
Crizotinib—MAP3K12—adrenal cortex—adrenal gland cancer	0.000368	0.00568	CbGeAlD
Crizotinib—ACVR1—adrenal cortex—adrenal gland cancer	0.000368	0.00568	CbGeAlD
Crizotinib—TAOK2—adrenal gland—adrenal gland cancer	0.000366	0.00565	CbGeAlD
Crizotinib—TYRO3—gonad—adrenal gland cancer	0.000358	0.00553	CbGeAlD
Crizotinib—FER—gonad—adrenal gland cancer	0.000358	0.00553	CbGeAlD
Crizotinib—FER—cardiac atrium—adrenal gland cancer	0.000358	0.00552	CbGeAlD
Crizotinib—EPHA3—adrenal gland—adrenal gland cancer	0.000353	0.00545	CbGeAlD
Crizotinib—ACVR1B—adrenal gland—adrenal gland cancer	0.000353	0.00545	CbGeAlD
Crizotinib—FER—pituitary gland—adrenal gland cancer	0.00035	0.0054	CbGeAlD
Crizotinib—ALK—pituitary gland—adrenal gland cancer	0.00035	0.0054	CbGeAlD
Crizotinib—EPHA5—pituitary gland—adrenal gland cancer	0.00035	0.0054	CbGeAlD
Crizotinib—TNK1—pituitary gland—adrenal gland cancer	0.000346	0.00534	CbGeAlD
Crizotinib—IGF1R—gonad—adrenal gland cancer	0.000344	0.00531	CbGeAlD
Crizotinib—JAK3—adrenal gland—adrenal gland cancer	0.000337	0.0052	CbGeAlD
Crizotinib—DCLK1—adrenal gland—adrenal gland cancer	0.000335	0.00516	CbGeAlD
Crizotinib—TIE1—cardiac atrium—adrenal gland cancer	0.000335	0.00516	CbGeAlD
Crizotinib—PLK4—adrenal gland—adrenal gland cancer	0.000333	0.00513	CbGeAlD
Crizotinib—MAP4K2—pituitary gland—adrenal gland cancer	0.000331	0.00511	CbGeAlD
Crizotinib—STK4—adrenal gland—adrenal gland cancer	0.000331	0.0051	CbGeAlD
Crizotinib—STK3—pituitary gland—adrenal gland cancer	0.000327	0.00504	CbGeAlD
Crizotinib—AURKA—gonad—adrenal gland cancer	0.000326	0.00504	CbGeAlD
Crizotinib—TESK1—gonad—adrenal gland cancer	0.000324	0.005	CbGeAlD
Crizotinib—TESK1—cardiac atrium—adrenal gland cancer	0.000323	0.00499	CbGeAlD
Crizotinib—AURKA—pituitary gland—adrenal gland cancer	0.000318	0.00491	CbGeAlD
Crizotinib—TESK1—pituitary gland—adrenal gland cancer	0.000316	0.00487	CbGeAlD
Crizotinib—FER—adrenal gland—adrenal gland cancer	0.000312	0.00482	CbGeAlD
Crizotinib—TNK1—adrenal gland—adrenal gland cancer	0.000309	0.00477	CbGeAlD
Crizotinib—TBK1—adrenal cortex—adrenal gland cancer	0.000309	0.00476	CbGeAlD
Crizotinib—LIMK2—gonad—adrenal gland cancer	0.000308	0.00475	CbGeAlD
Crizotinib—MERTK—pituitary gland—adrenal gland cancer	0.000307	0.00474	CbGeAlD
Crizotinib—TYK2—adrenal cortex—adrenal gland cancer	0.000307	0.00473	CbGeAlD
Crizotinib—BMPR1B—adrenal gland—adrenal gland cancer	0.000306	0.00472	CbGeAlD
Crizotinib—MAP4K1—adrenal gland—adrenal gland cancer	0.000306	0.00472	CbGeAlD
Crizotinib—MAP3K12—gonad—adrenal gland cancer	0.000305	0.0047	CbGeAlD
Crizotinib—FLT3—gonad—adrenal gland cancer	0.000305	0.0047	CbGeAlD
Crizotinib—MAP3K12—cardiac atrium—adrenal gland cancer	0.000304	0.0047	CbGeAlD
Crizotinib—ACVR1—cardiac atrium—adrenal gland cancer	0.000304	0.0047	CbGeAlD
Crizotinib—LIMK2—pituitary gland—adrenal gland cancer	0.000301	0.00464	CbGeAlD
Crizotinib—TNK2—adrenal gland—adrenal gland cancer	0.0003	0.00463	CbGeAlD
Crizotinib—IGF1R—adrenal gland—adrenal gland cancer	0.0003	0.00463	CbGeAlD
Crizotinib—NUAK2—pituitary gland—adrenal gland cancer	0.000299	0.00462	CbGeAlD
Crizotinib—STK35—gonad—adrenal gland cancer	0.000299	0.00461	CbGeAlD
Crizotinib—STK35—cardiac atrium—adrenal gland cancer	0.000298	0.0046	CbGeAlD
Crizotinib—MAP3K12—pituitary gland—adrenal gland cancer	0.000297	0.00459	CbGeAlD
Crizotinib—ACVR1—pituitary gland—adrenal gland cancer	0.000297	0.00459	CbGeAlD
Crizotinib—RPS6KB1—adrenal cortex—adrenal gland cancer	0.000297	0.00458	CbGeAlD
Crizotinib—MAP4K2—adrenal gland—adrenal gland cancer	0.000296	0.00457	CbGeAlD
Crizotinib—AXL—adrenal cortex—adrenal gland cancer	0.000294	0.00453	CbGeAlD
Crizotinib—STK3—adrenal gland—adrenal gland cancer	0.000292	0.00451	CbGeAlD
Crizotinib—TIE1—adrenal gland—adrenal gland cancer	0.000292	0.00451	CbGeAlD
Crizotinib—BMP2K—gonad—adrenal gland cancer	0.000287	0.00443	CbGeAlD
Crizotinib—AURKA—adrenal gland—adrenal gland cancer	0.000285	0.00439	CbGeAlD
Crizotinib—ABL2—pituitary gland—adrenal gland cancer	0.000284	0.00438	CbGeAlD
Crizotinib—SLK—adrenal cortex—adrenal gland cancer	0.000283	0.00436	CbGeAlD
Crizotinib—TESK1—adrenal gland—adrenal gland cancer	0.000282	0.00435	CbGeAlD
Crizotinib—CYP3A4—urine—adrenal gland cancer	0.000281	0.00434	CbGeAlD
Crizotinib—EPHB4—adrenal cortex—adrenal gland cancer	0.000281	0.00433	CbGeAlD
Crizotinib—PTK2B—gonad—adrenal gland cancer	0.000278	0.00428	CbGeAlD
Crizotinib—EPHA2—adrenal cortex—adrenal gland cancer	0.000276	0.00425	CbGeAlD
Crizotinib—RIPK2—cardiac atrium—adrenal gland cancer	0.000275	0.00424	CbGeAlD
Crizotinib—MERTK—adrenal gland—adrenal gland cancer	0.000274	0.00424	CbGeAlD
Crizotinib—TEK—adrenal cortex—adrenal gland cancer	0.000269	0.00415	CbGeAlD
Crizotinib—MAP3K3—adrenal cortex—adrenal gland cancer	0.000269	0.00415	CbGeAlD
Crizotinib—RIPK2—pituitary gland—adrenal gland cancer	0.000269	0.00414	CbGeAlD
Crizotinib—LIMK2—adrenal gland—adrenal gland cancer	0.000268	0.00414	CbGeAlD
Crizotinib—NUAK2—adrenal gland—adrenal gland cancer	0.000267	0.00413	CbGeAlD
Crizotinib—EPHA4—gonad—adrenal gland cancer	0.000266	0.00411	CbGeAlD
Crizotinib—EPHA4—cardiac atrium—adrenal gland cancer	0.000266	0.0041	CbGeAlD
Crizotinib—ACVR1—adrenal gland—adrenal gland cancer	0.000266	0.0041	CbGeAlD
Crizotinib—MAP3K12—adrenal gland—adrenal gland cancer	0.000266	0.0041	CbGeAlD
Crizotinib—FLT3—adrenal gland—adrenal gland cancer	0.000266	0.0041	CbGeAlD
Crizotinib—MAP3K2—gonad—adrenal gland cancer	0.000261	0.00403	CbGeAlD
Crizotinib—STK35—adrenal gland—adrenal gland cancer	0.00026	0.00402	CbGeAlD
Crizotinib—EPHA4—pituitary gland—adrenal gland cancer	0.00026	0.00401	CbGeAlD
Crizotinib—PTK2—gonad—adrenal gland cancer	0.000256	0.00394	CbGeAlD
Crizotinib—TBK1—gonad—adrenal gland cancer	0.000256	0.00394	CbGeAlD
Crizotinib—TBK1—cardiac atrium—adrenal gland cancer	0.000255	0.00394	CbGeAlD
Crizotinib—ABL2—adrenal gland—adrenal gland cancer	0.000254	0.00391	CbGeAlD
Crizotinib—TYK2—cardiac atrium—adrenal gland cancer	0.000254	0.00391	CbGeAlD
Crizotinib—BMP2K—adrenal gland—adrenal gland cancer	0.00025	0.00387	CbGeAlD
Crizotinib—TBK1—pituitary gland—adrenal gland cancer	0.000249	0.00385	CbGeAlD
Crizotinib—PTK2—pituitary gland—adrenal gland cancer	0.000249	0.00385	CbGeAlD
Crizotinib—YES1—adrenal cortex—adrenal gland cancer	0.000248	0.00383	CbGeAlD
Crizotinib—TYK2—pituitary gland—adrenal gland cancer	0.000248	0.00382	CbGeAlD
Crizotinib—RPS6KB1—cardiac atrium—adrenal gland cancer	0.000246	0.00379	CbGeAlD
Crizotinib—TAOK3—adrenal cortex—adrenal gland cancer	0.000245	0.00378	CbGeAlD
Crizotinib—AXL—gonad—adrenal gland cancer	0.000243	0.00376	CbGeAlD
Crizotinib—AXL—cardiac atrium—adrenal gland cancer	0.000243	0.00375	CbGeAlD
Crizotinib—PTK2B—adrenal gland—adrenal gland cancer	0.000242	0.00373	CbGeAlD
Crizotinib—RIPK2—adrenal gland—adrenal gland cancer	0.00024	0.0037	CbGeAlD
Crizotinib—RPS6KB1—pituitary gland—adrenal gland cancer	0.00024	0.0037	CbGeAlD
Crizotinib—FGR—pituitary gland—adrenal gland cancer	0.000238	0.00368	CbGeAlD
Crizotinib—AXL—pituitary gland—adrenal gland cancer	0.000237	0.00366	CbGeAlD
Crizotinib—SLK—cardiac atrium—adrenal gland cancer	0.000234	0.00361	CbGeAlD
Crizotinib—EPHB4—cardiac atrium—adrenal gland cancer	0.000232	0.00358	CbGeAlD
Crizotinib—EPHA4—adrenal gland—adrenal gland cancer	0.000232	0.00358	CbGeAlD
Crizotinib—JAK2—gonad—adrenal gland cancer	0.000231	0.00356	CbGeAlD
Crizotinib—JAK2—cardiac atrium—adrenal gland cancer	0.000231	0.00356	CbGeAlD
Crizotinib—SLK—pituitary gland—adrenal gland cancer	0.000229	0.00353	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—adrenal gland cancer	0.000228	0.00352	CbGeAlD
Crizotinib—MAP3K2—adrenal gland—adrenal gland cancer	0.000227	0.00351	CbGeAlD
Crizotinib—EPHB4—pituitary gland—adrenal gland cancer	0.000227	0.0035	CbGeAlD
Crizotinib—JAK2—pituitary gland—adrenal gland cancer	0.000225	0.00348	CbGeAlD
Crizotinib—PTK2—adrenal gland—adrenal gland cancer	0.000223	0.00344	CbGeAlD
Crizotinib—TBK1—adrenal gland—adrenal gland cancer	0.000223	0.00344	CbGeAlD
Crizotinib—EPHA2—pituitary gland—adrenal gland cancer	0.000223	0.00344	CbGeAlD
Crizotinib—MAP4K5—gonad—adrenal gland cancer	0.000223	0.00344	CbGeAlD
Crizotinib—MAP3K3—gonad—adrenal gland cancer	0.000223	0.00344	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—adrenal gland cancer	0.000222	0.00343	CbGeAlD
Crizotinib—MAP3K3—cardiac atrium—adrenal gland cancer	0.000222	0.00343	CbGeAlD
Crizotinib—TEK—cardiac atrium—adrenal gland cancer	0.000222	0.00343	CbGeAlD
Crizotinib—TYK2—adrenal gland—adrenal gland cancer	0.000221	0.00341	CbGeAlD
Crizotinib—IRAK1—adrenal gland—adrenal gland cancer	0.000218	0.00337	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—adrenal gland cancer	0.000217	0.00335	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—adrenal gland cancer	0.000217	0.00335	CbGeAlD
Crizotinib—TEK—pituitary gland—adrenal gland cancer	0.000217	0.00335	CbGeAlD
Crizotinib—CSF1R—adrenal cortex—adrenal gland cancer	0.000214	0.00331	CbGeAlD
Crizotinib—RPS6KB1—adrenal gland—adrenal gland cancer	0.000214	0.00331	CbGeAlD
Crizotinib—FGR—adrenal gland—adrenal gland cancer	0.000213	0.00329	CbGeAlD
Crizotinib—LCK—adrenal gland—adrenal gland cancer	0.000213	0.00329	CbGeAlD
Crizotinib—EPHB6—cardiac atrium—adrenal gland cancer	0.000212	0.00328	CbGeAlD
Crizotinib—AXL—adrenal gland—adrenal gland cancer	0.000212	0.00327	CbGeAlD
Crizotinib—EPHB6—pituitary gland—adrenal gland cancer	0.000208	0.0032	CbGeAlD
Crizotinib—YES1—gonad—adrenal gland cancer	0.000206	0.00317	CbGeAlD
Crizotinib—YES1—cardiac atrium—adrenal gland cancer	0.000205	0.00317	CbGeAlD
Crizotinib—SLK—adrenal gland—adrenal gland cancer	0.000204	0.00315	CbGeAlD
Crizotinib—STK10—gonad—adrenal gland cancer	0.000204	0.00314	CbGeAlD
Crizotinib—EPHB4—adrenal gland—adrenal gland cancer	0.000203	0.00313	CbGeAlD
Crizotinib—TAOK3—cardiac atrium—adrenal gland cancer	0.000203	0.00313	CbGeAlD
Crizotinib—JAK2—adrenal gland—adrenal gland cancer	0.000201	0.00311	CbGeAlD
Crizotinib—YES1—pituitary gland—adrenal gland cancer	0.000201	0.00309	CbGeAlD
Crizotinib—EPHA2—adrenal gland—adrenal gland cancer	0.000199	0.00307	CbGeAlD
Crizotinib—TAOK3—pituitary gland—adrenal gland cancer	0.000198	0.00306	CbGeAlD
Crizotinib—SRC—gonad—adrenal gland cancer	0.000198	0.00305	CbGeAlD
Crizotinib—SRC—cardiac atrium—adrenal gland cancer	0.000198	0.00305	CbGeAlD
Crizotinib—MAP3K3—adrenal gland—adrenal gland cancer	0.000194	0.00299	CbGeAlD
Crizotinib—TEK—adrenal gland—adrenal gland cancer	0.000194	0.00299	CbGeAlD
Crizotinib—MAP4K5—adrenal gland—adrenal gland cancer	0.000194	0.00299	CbGeAlD
Crizotinib—EPHB6—adrenal gland—adrenal gland cancer	0.000185	0.00286	CbGeAlD
Crizotinib—YES1—adrenal gland—adrenal gland cancer	0.000179	0.00276	CbGeAlD
Crizotinib—STK10—adrenal gland—adrenal gland cancer	0.000178	0.00274	CbGeAlD
Crizotinib—CSF1R—gonad—adrenal gland cancer	0.000178	0.00274	CbGeAlD
Crizotinib—CSF1R—cardiac atrium—adrenal gland cancer	0.000177	0.00274	CbGeAlD
Crizotinib—TAOK3—adrenal gland—adrenal gland cancer	0.000177	0.00273	CbGeAlD
Crizotinib—CSF1R—pituitary gland—adrenal gland cancer	0.000173	0.00267	CbGeAlD
Crizotinib—SRC—adrenal gland—adrenal gland cancer	0.000172	0.00266	CbGeAlD
Crizotinib—ABL1—adrenal cortex—adrenal gland cancer	0.000169	0.00261	CbGeAlD
Crizotinib—CSF1R—adrenal gland—adrenal gland cancer	0.000155	0.00239	CbGeAlD
Crizotinib—ABL1—gonad—adrenal gland cancer	0.00014	0.00217	CbGeAlD
Crizotinib—ABL1—cardiac atrium—adrenal gland cancer	0.00014	0.00216	CbGeAlD
Crizotinib—ABL1—pituitary gland—adrenal gland cancer	0.000137	0.00211	CbGeAlD
Crizotinib—ABL1—adrenal gland—adrenal gland cancer	0.000122	0.00189	CbGeAlD
Crizotinib—ABCB1—adrenal cortex—adrenal gland cancer	5.27e-05	0.000813	CbGeAlD
Crizotinib—ABCB1—gonad—adrenal gland cancer	4.36e-05	0.000673	CbGeAlD
Crizotinib—ABCB1—pituitary gland—adrenal gland cancer	4.26e-05	0.000657	CbGeAlD
Crizotinib—ABCB1—adrenal gland—adrenal gland cancer	3.8e-05	0.000587	CbGeAlD
Crizotinib—BMPR1B—Signaling Pathways—EGFR—adrenal gland cancer	3.89e-06	3.94e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—BRAF—adrenal gland cancer	3.88e-06	3.94e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDC42—adrenal gland cancer	3.88e-06	3.94e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—CTNNB1—adrenal gland cancer	3.88e-06	3.94e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CTNNB1—adrenal gland cancer	3.87e-06	3.92e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—BAD—adrenal gland cancer	3.87e-06	3.92e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—EGFR—adrenal gland cancer	3.86e-06	3.92e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—EGFR—adrenal gland cancer	3.86e-06	3.92e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF2—adrenal gland cancer	3.85e-06	3.91e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TP53—adrenal gland cancer	3.85e-06	3.91e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SPRY2—adrenal gland cancer	3.85e-06	3.9e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PRKACA—adrenal gland cancer	3.84e-06	3.89e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—CTNNB1—adrenal gland cancer	3.83e-06	3.89e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—GNAS—adrenal gland cancer	3.82e-06	3.87e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—CTNNB1—adrenal gland cancer	3.82e-06	3.87e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CTNNB1—adrenal gland cancer	3.81e-06	3.87e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—EGFR—adrenal gland cancer	3.8e-06	3.86e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—BAD—adrenal gland cancer	3.8e-06	3.86e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—CTNNB1—adrenal gland cancer	3.8e-06	3.85e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TP53—adrenal gland cancer	3.8e-06	3.85e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TP53—adrenal gland cancer	3.77e-06	3.82e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TP53—adrenal gland cancer	3.77e-06	3.82e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—EGFR—adrenal gland cancer	3.76e-06	3.82e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—EGFR—adrenal gland cancer	3.75e-06	3.8e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSHR—adrenal gland cancer	3.75e-06	3.8e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—BAD—adrenal gland cancer	3.75e-06	3.8e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—CTNNB1—adrenal gland cancer	3.74e-06	3.8e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF2—adrenal gland cancer	3.74e-06	3.79e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	3.74e-06	3.79e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF1R—adrenal gland cancer	3.73e-06	3.78e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—CTNNB1—adrenal gland cancer	3.72e-06	3.77e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—CTNNB1—adrenal gland cancer	3.71e-06	3.76e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—GNAS—adrenal gland cancer	3.71e-06	3.76e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PRKACA—adrenal gland cancer	3.71e-06	3.76e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CDC42—adrenal gland cancer	3.68e-06	3.73e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—EGFR—adrenal gland cancer	3.65e-06	3.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF1R—adrenal gland cancer	3.62e-06	3.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CTNNB1—adrenal gland cancer	3.59e-06	3.64e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—BAD—adrenal gland cancer	3.59e-06	3.64e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—adrenal gland cancer	3.57e-06	3.62e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—POMC—adrenal gland cancer	3.53e-06	3.58e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDC42—adrenal gland cancer	3.53e-06	3.58e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MEN1—adrenal gland cancer	3.52e-06	3.57e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—BRAF—adrenal gland cancer	3.52e-06	3.57e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—POMC—adrenal gland cancer	3.51e-06	3.55e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—RRM1—adrenal gland cancer	3.5e-06	3.55e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SDHD—adrenal gland cancer	3.5e-06	3.55e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—EGFR—adrenal gland cancer	3.5e-06	3.55e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—BAD—adrenal gland cancer	3.48e-06	3.53e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PRKACA—adrenal gland cancer	3.47e-06	3.52e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—BRAF—adrenal gland cancer	3.46e-06	3.51e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MED12—adrenal gland cancer	3.46e-06	3.5e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—POMC—adrenal gland cancer	3.45e-06	3.5e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—EGFR—adrenal gland cancer	3.44e-06	3.49e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—EGFR—adrenal gland cancer	3.44e-06	3.49e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TERT—adrenal gland cancer	3.43e-06	3.48e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—EGFR—adrenal gland cancer	3.42e-06	3.47e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—BRAF—adrenal gland cancer	3.41e-06	3.46e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—EGFR—adrenal gland cancer	3.4e-06	3.45e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—BAD—adrenal gland cancer	3.39e-06	3.44e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TERT—adrenal gland cancer	3.38e-06	3.43e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—BAD—adrenal gland cancer	3.38e-06	3.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TERT—adrenal gland cancer	3.37e-06	3.42e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SDHB—adrenal gland cancer	3.35e-06	3.39e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—POMC—adrenal gland cancer	3.31e-06	3.35e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	3.29e-06	3.34e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—adrenal gland cancer	3.27e-06	3.31e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—BRAF—adrenal gland cancer	3.26e-06	3.31e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CDC42—adrenal gland cancer	3.26e-06	3.3e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—EGFR—adrenal gland cancer	3.22e-06	3.26e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TERT—adrenal gland cancer	3.21e-06	3.25e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—POMC—adrenal gland cancer	3.21e-06	3.25e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—POMC—adrenal gland cancer	3.2e-06	3.25e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—BAD—adrenal gland cancer	3.18e-06	3.22e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—BRAF—adrenal gland cancer	3.17e-06	3.21e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	3.16e-06	3.2e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—CTNNB1—adrenal gland cancer	3.15e-06	3.19e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDC42—adrenal gland cancer	3.14e-06	3.19e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CTNNB1—adrenal gland cancer	3.14e-06	3.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TERT—adrenal gland cancer	3.11e-06	3.16e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EGFR—adrenal gland cancer	3.08e-06	3.12e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EGFR—adrenal gland cancer	3.07e-06	3.11e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PRKACA—adrenal gland cancer	3.04e-06	3.08e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—EGFR—adrenal gland cancer	3.04e-06	3.08e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CTNNB1—adrenal gland cancer	3.04e-06	3.08e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF2—adrenal gland cancer	3.03e-06	3.07e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—EGFR—adrenal gland cancer	3.02e-06	3.06e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—EGFR—adrenal gland cancer	3.02e-06	3.06e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EGFR—adrenal gland cancer	3.01e-06	3.05e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—GNAS—adrenal gland cancer	3e-06	3.05e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CTNNB1—adrenal gland cancer	2.99e-06	3.04e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—BAD—adrenal gland cancer	2.98e-06	3.03e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—EGFR—adrenal gland cancer	2.97e-06	3.01e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TERT—adrenal gland cancer	2.95e-06	2.99e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—EGFR—adrenal gland cancer	2.95e-06	2.99e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—BAD—adrenal gland cancer	2.94e-06	2.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDC42—adrenal gland cancer	2.94e-06	2.98e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—EGFR—adrenal gland cancer	2.94e-06	2.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—BAD—adrenal gland cancer	2.93e-06	2.97e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1R—adrenal gland cancer	2.93e-06	2.97e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—EGFR—adrenal gland cancer	2.92e-06	2.96e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—adrenal gland cancer	2.86e-06	2.9e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTGS2—adrenal gland cancer	2.84e-06	2.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—EGFR—adrenal gland cancer	2.84e-06	2.88e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CTNNB1—adrenal gland cancer	2.84e-06	2.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF2—adrenal gland cancer	2.84e-06	2.88e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—adrenal gland cancer	2.83e-06	2.87e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—adrenal gland cancer	2.82e-06	2.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—GNAS—adrenal gland cancer	2.81e-06	2.85e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CTNNB1—adrenal gland cancer	2.81e-06	2.85e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—BAD—adrenal gland cancer	2.79e-06	2.83e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CTNNB1—adrenal gland cancer	2.78e-06	2.82e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—BAD—adrenal gland cancer	2.78e-06	2.82e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CTNNB1—adrenal gland cancer	2.76e-06	2.8e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—POMC—adrenal gland cancer	2.75e-06	2.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1R—adrenal gland cancer	2.74e-06	2.78e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—BRAF—adrenal gland cancer	2.72e-06	2.75e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—POMC—adrenal gland cancer	2.71e-06	2.75e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—BAD—adrenal gland cancer	2.71e-06	2.75e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRKACA—adrenal gland cancer	2.69e-06	2.73e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—BRAF—adrenal gland cancer	2.68e-06	2.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—BRAF—adrenal gland cancer	2.67e-06	2.71e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	2.65e-06	2.69e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—adrenal gland cancer	2.65e-06	2.69e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TERT—adrenal gland cancer	2.61e-06	2.65e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MED12—adrenal gland cancer	2.61e-06	2.64e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—adrenal gland cancer	2.58e-06	2.62e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDC42—adrenal gland cancer	2.58e-06	2.61e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—POMC—adrenal gland cancer	2.57e-06	2.61e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—BAD—adrenal gland cancer	2.57e-06	2.6e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CTNNB1—adrenal gland cancer	2.55e-06	2.58e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—BRAF—adrenal gland cancer	2.54e-06	2.58e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—adrenal gland cancer	2.53e-06	2.56e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TERT—adrenal gland cancer	2.52e-06	2.56e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PRKACA—adrenal gland cancer	2.52e-06	2.56e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CTNNB1—adrenal gland cancer	2.5e-06	2.54e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—POMC—adrenal gland cancer	2.5e-06	2.53e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—adrenal gland cancer	2.5e-06	2.53e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—adrenal gland cancer	2.49e-06	2.52e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF2—adrenal gland cancer	2.48e-06	2.52e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—BRAF—adrenal gland cancer	2.47e-06	2.5e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CTNNB1—adrenal gland cancer	2.47e-06	2.5e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—BAD—adrenal gland cancer	2.46e-06	2.5e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—GNAS—adrenal gland cancer	2.46e-06	2.5e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—adrenal gland cancer	2.41e-06	2.44e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1R—adrenal gland cancer	2.4e-06	2.43e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—adrenal gland cancer	2.39e-06	2.42e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—adrenal gland cancer	2.39e-06	2.42e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—adrenal gland cancer	2.37e-06	2.41e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TERT—adrenal gland cancer	2.36e-06	2.39e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CTNNB1—adrenal gland cancer	2.36e-06	2.39e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—BRAF—adrenal gland cancer	2.34e-06	2.37e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—adrenal gland cancer	2.32e-06	2.35e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CTNNB1—adrenal gland cancer	2.29e-06	2.32e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDC42—adrenal gland cancer	2.28e-06	2.31e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—BAD—adrenal gland cancer	2.27e-06	2.31e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—adrenal gland cancer	2.25e-06	2.28e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTNNB1—adrenal gland cancer	2.23e-06	2.26e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—adrenal gland cancer	2.22e-06	2.25e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTNNB1—adrenal gland cancer	2.22e-06	2.25e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—adrenal gland cancer	2.2e-06	2.23e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF2—adrenal gland cancer	2.2e-06	2.23e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—BAD—adrenal gland cancer	2.19e-06	2.22e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—adrenal gland cancer	2.18e-06	2.21e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—GNAS—adrenal gland cancer	2.18e-06	2.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—adrenal gland cancer	2.16e-06	2.19e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SDHD—adrenal gland cancer	2.16e-06	2.19e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RRM1—adrenal gland cancer	2.16e-06	2.19e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1R—adrenal gland cancer	2.13e-06	2.16e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—adrenal gland cancer	2.12e-06	2.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTNNB1—adrenal gland cancer	2.09e-06	2.12e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—BRAF—adrenal gland cancer	2.07e-06	2.1e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TERT—adrenal gland cancer	2.07e-06	2.1e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—adrenal gland cancer	2.06e-06	2.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—BAD—adrenal gland cancer	2.05e-06	2.08e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GNAS—adrenal gland cancer	2.04e-06	2.07e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—adrenal gland cancer	2.02e-06	2.05e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—adrenal gland cancer	2.02e-06	2.04e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ABCB1—adrenal gland cancer	2.01e-06	2.03e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—BRAF—adrenal gland cancer	2e-06	2.03e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—adrenal gland cancer	1.98e-06	2.01e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CTNNB1—adrenal gland cancer	1.96e-06	1.99e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—adrenal gland cancer	1.95e-06	1.98e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CTNNB1—adrenal gland cancer	1.94e-06	1.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CTNNB1—adrenal gland cancer	1.93e-06	1.96e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PRKACA—adrenal gland cancer	1.9e-06	1.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—adrenal gland cancer	1.89e-06	1.92e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—adrenal gland cancer	1.89e-06	1.91e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—adrenal gland cancer	1.87e-06	1.9e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—BRAF—adrenal gland cancer	1.87e-06	1.9e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—adrenal gland cancer	1.87e-06	1.89e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CTNNB1—adrenal gland cancer	1.84e-06	1.86e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TERT—adrenal gland cancer	1.83e-06	1.86e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTNNB1—adrenal gland cancer	1.83e-06	1.86e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—adrenal gland cancer	1.81e-06	1.84e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—adrenal gland cancer	1.81e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BAD—adrenal gland cancer	1.8e-06	1.82e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CTNNB1—adrenal gland cancer	1.78e-06	1.81e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—adrenal gland cancer	1.77e-06	1.79e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—adrenal gland cancer	1.76e-06	1.79e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CTNNB1—adrenal gland cancer	1.69e-06	1.71e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—adrenal gland cancer	1.67e-06	1.69e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—adrenal gland cancer	1.66e-06	1.69e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—adrenal gland cancer	1.66e-06	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—adrenal gland cancer	1.66e-06	1.68e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—adrenal gland cancer	1.64e-06	1.66e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BRAF—adrenal gland cancer	1.64e-06	1.66e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTNNB1—adrenal gland cancer	1.62e-06	1.64e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MED12—adrenal gland cancer	1.61e-06	1.63e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BAD—adrenal gland cancer	1.59e-06	1.61e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—adrenal gland cancer	1.57e-06	1.59e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—adrenal gland cancer	1.56e-06	1.58e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNAS—adrenal gland cancer	1.54e-06	1.56e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—adrenal gland cancer	1.53e-06	1.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—adrenal gland cancer	1.53e-06	1.55e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—adrenal gland cancer	1.52e-06	1.54e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—adrenal gland cancer	1.5e-06	1.52e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—adrenal gland cancer	1.47e-06	1.49e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—adrenal gland cancer	1.45e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—adrenal gland cancer	1.45e-06	1.47e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—adrenal gland cancer	1.45e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—adrenal gland cancer	1.44e-06	1.46e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—adrenal gland cancer	1.41e-06	1.43e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—adrenal gland cancer	1.38e-06	1.4e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—adrenal gland cancer	1.35e-06	1.37e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—adrenal gland cancer	1.34e-06	1.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—adrenal gland cancer	1.31e-06	1.32e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—adrenal gland cancer	1.29e-06	1.31e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—adrenal gland cancer	1.28e-06	1.3e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—adrenal gland cancer	1.22e-06	1.24e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—adrenal gland cancer	1.19e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—adrenal gland cancer	1.19e-06	1.2e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—adrenal gland cancer	1.18e-06	1.2e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	1.17e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—adrenal gland cancer	1.14e-06	1.16e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—adrenal gland cancer	1.1e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—adrenal gland cancer	1.07e-06	1.09e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—adrenal gland cancer	1.05e-06	1.06e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—adrenal gland cancer	1.04e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—adrenal gland cancer	9.6e-07	9.74e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAS—adrenal gland cancer	9.5e-07	9.63e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—adrenal gland cancer	9.37e-07	9.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	9.32e-07	9.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—adrenal gland cancer	8.99e-07	9.11e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—adrenal gland cancer	8.3e-07	8.41e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—adrenal gland cancer	8.28e-07	8.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—adrenal gland cancer	7.87e-07	7.98e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—adrenal gland cancer	6.97e-07	7.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—adrenal gland cancer	6.4e-07	6.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	5.1e-07	5.17e-06	CbGpPWpGaD
